Unlocking the potential of cell therapy

Meet our leadership team

• 

  MA MBA

  Mark Rothera

  Chief Executive Officer

  Mark Rothera is Chief Executive Officer and Director of TreeFrog Therapeutics. He was appointed to this position in December 2025.

  Mark brings more than 35 years of experience in the biopharmaceutical industry, with a strong record of driving the successful scaling of multiple biotech companies in both private and public settings, enabling the development and commercialization of novel medicines for specialized conditions. TreeFrog is his fourth CEO role. In his previous role, he was President and CEO of Viracta (Nasdaq: VIRX) a clinical-stage oncology company. and President and CEO of Silence Therapeutics (NASDAQ: SLN), a clinical-stage RNAi platform company developing therapies for hematology, cardiovascular and rare diseases and partnering the platform with leading Pharma companies on their targets of interest. Mark’s first CEO & President role was with Orchard Therapeutics (NASDAQ: ORTX), overseeing its transformation from a small U.K.-based, privately held company into a leading transatlantic, public, gene therapy company. Prior to Orchard, He served as Chief Commercial Officer of PTC Therapeutics (NASDAQ: PTCT), launching two rare disease therapies. His earlier roles included Global President of Aegerion Pharmaceuticals Inc.,  and Vice President and General Manager of commercial operations at Shire Human Genetic Therapies for Europe, Middle East and Africa. He Rothera received an M.A. in Natural Sciences from Cambridge University and an M.B.A. from the European Institute for Business Administration (INSEAD).

• 

  MSc

  Myriam Makhloufi

  Chief Strategy Officer

  Myriam joined TreeFrog Therapeutics as Chief Strategy Officer in November 2021.

  With over 20 year’s experience in Life Sciences, Myriam kicked off her career with Bionest Partners as a Management Consultant in charge of the commercial and strategic due diligence department for private equity clients. During her tenure, she gained deep insight into a wide variety of large, midsize and small pharmaceutical companies, in particular in target positioning, portfolio assessment and strategy development. She then moved into the Financial Advisory Services arm of the company, focusing on merger & acquisitions.

  In 2011, Myriam joined Astellas Pharma to lead the Market Research and Strategic Planning department, before being appointed as Corporate Development, Licensing & Acquisition Director for Pierre Fabre Medicament in 2015. Prior to joining Treefrog Therapeutics, Myriam sat on the management team of Seqens, a contract development and manufacturing operations company, where she held the position of Strategic and Operational Marketing Director.

  Myriam completed a DEUG in Life Sciences from Université Jussieu, Paris and holds a MSc in Biotechnology and Management from ESIEE management (formerly Institut Superieur de Technologie et Management ISTM, Paris).

• 

  MBA

  Michael Lanero Fidalgo

  Chief Operating Officer

  Michaël joined TreeFrog Therapeutics in early 2020 as Chief Operating Officer.

  Michaël is responsible for leading process development & analytics activities as well as technical development related to the core technology of the company (SAKURA®). He is also in charge of the technical services – IS/IT, supply chain & Infrastructure management.

  Michaël is renowned for his capability to bring innovative approaches to any project. Prior to joining TreeFrog, he headed up the EMEA Bio Development Center in France for Merck, focused on scaling up an innovative business through seeding new technology applications and services, ultimately growing the business at 25% CAGR. He was also in charge of defining strategy across all core business functions including process development, GMP manufacturing, supply chain, quality and supporting sales functions.

  In another of his positions with Merck, he created the first microbial process development laboratory to deal with therapeutic drug development in the MERCK KGaA healthcare business unit covering process development, analytical, quality, biostatistics and project management.

  Michaël started his career at GlaxoSmithKline Biologicals in Belgium where he worked for 10 years in several positions in the R&D organization focused primarily on vaccines process development and driving technological innovation in the field, as well as working as an expert for commercial product cycle management.

• 

  MBA

  Daniel Castro

  Chief Business Officer

  Daniel joined TreeFrog Therapeutics as Chief Business Officer in March 2023.

  Prior to joining TreeFrog Therapeutics, Dan was the Chief Business Officer at Avectas, a cell engineering company based in Dublin, Ireland, where he led corporate strategy and business development.
   
  Previously, Dan spent 15 years at Mass General Brigham (MGB), a teaching hospital of Harvard Medical School, where he led a 30-person business development team as Managing Director.  Prior to MGB, Dan spent more than 10 years within the biopharma industry, including roles at Sanofi, Agenus and Onyx Pharmaceuticals (now Amgen). 
   
  Dan holds a Bachelor of Science degree in Microbiology from the University of California, Davis, and a Master’s in Business Administration from Boston College.

• 

  PharmD, MSc

  François Gianelli

  Chief Regulatory and Quality Officer

  François joined TreeFrog Therapeutics as a consultant in 2019 and was appointed Chief Regulatory & Quality Officer in January 2023.

  With 15 years experience in Regulatory Science for Cell and Gene Therapy, François began his career in the French army health services and the French Medicine Agency (ANSM). As part of the cell therapy quality control laboratory, he supported the establishment of new cell therapy guidelines.

  In 2013, François joined Voisin Consulting Life Sciences (VCLS) where his expertise in cell and gene therapy requirements and challenges actively supported building the regulatory chemistry, manufacturing and controls (CMC) expertise within the company where he worked on multiple cell and gene therapies. He was responsible for communicating with regulatory authorities, authoring and reviewing CMC content (IMPD/IND and MAA/NDA/BLA), performing gap-analysis, product positioning and establishing pragmatic regulatory strategy. His most recent position was Head of the European CMC division. François is a recognized speaker and trainer on Cell and Gene Therapy development at international conferences. François holds a Pharm.D. from the University of Pharmacy Paris-V and two MSc Degrees, in pharmaceutical biotechnology and innovative therapies and in human genetics from University of Paris-XI.

• 

  MD, PhD

  Jens Schröder

  Chief Medical Officer

  Jens joined TreeFrog Therapeutics as Chief Medical Officer in July 2023

  Jens brings 20 years of experience in the healthcare sector and joins from Bayer where he was responsible for the Clinical Development of the cell therapy portfolio. In 2003, he began his career at Ethicon, a medical device company subsidiary of Johnson & Johnson, where he was responsible for innovative and complex device development programs.

  Jens joined Bayer in Montville, New Jersey, in 2007. During his 15-year tenure, he held various leadership positions in late-stage clinical development of numerous products, including Spheramine®, which was Bayer’s pioneering work on cell therapy for Parkinson’s Disease.

  In 2017, while retaining his corporate role at Bayer, he co-founded Coagulant Therapeutics, Inc., a privately-held company developing medicines to treat acute bleeding, as part of a spin-off from Bayer. Jens has also served as an advisor to several emerging medical technology firms, advancing their product development programs and processes.

  Jens, a German national, holds an MD from Hamburg University School of Medicine and a PhD from the Institute for Immunology at Hamburg University. He is a trained Neurosurgeon and Molecular Biologist.

• 

  Rachel Mooney

  Chief Communications Officer

  Rachel joined Treefrog Therapeutics as Chief Communications Officer in September 2023.

  With nearly 25 years’ experience in communications and marketing, Rachel started her career on the agency side, working across a wide range of areas including Government, finance, FMCG and Healthcare industries. Since 2003, she has focused on healthcare communications and joined Sanofi as Head of Communications & Public Affairs in Ireland in 2005, before moving to France as Global Marketing Manager for the Diabetes division in 2007. She joined the Global Communications Leadership team in 2009 as Head of CEO Communications & Strategic Communications Planning, a post she held for five years before ultimately leading International Communications, covering all country communications structures outside North America and France. Her last position at Sanofi was as Head of Consumer Healthcare Communications. Throughout her career at Sanofi, Rachel additionally led several initiatives around M&A, integration communications, culture evolution and issues management. Prior to joining TreeFrog, she spent two years as Head of Franchise Communications for Galderma. Rachel is Irish and a graduate in Business & Politics from Trinity College Dublin.

• 

  Romain Boiteux

  People Director

  Romain joined Treefrog in September 2022 to structure the Human Resources function and organize the teams to support the company’s development.

  Romain graduated from the University of Versailles in France in 2007 with a Master’s degree in law. He began his career in human resources at Leyton, a fast-growing international consultancy, where he held positions in personnel management, social partner relations and human resources development (recruitment, career management). In 2015, he moved to Bordeaux with his family to join Idaia, in the data marketing and communications sectors, to set up the human resources team, first on his own and then with a small team.

  Romain is passionate about the human resource challenges in developing a company, especially when innovation is at the heart of the future company: building the organization by anticipating the next phases of development, recruiting and retaining talent, building the social policy, supporting managers and the management team. Each phase of development brings its own set of new cultural, organizational, legal and relational challenges.

• 

  PhD

  Peter Andersen

  Chief Research & Development Officer

  Peter joined TreeFrog Therapeutics as Chief Research & Development Officer in July 2024.

  Peter brings over 15 years of expertise in stem cell biology and regenerative medicine, acquired from both academic and industry settings.
  During his tenure at the Johns Hopkins University, Baltimore, Peter co-founded Vita Therapeutics, Inc., a pioneering biotechnology company dedicated to developing regenerative iPSC-based cell-therapies for degenerative neuromuscular disorders. Serving as Chief Scientific Officer at Vita for five years, Peter oversaw all aspects of research and development, including pre-clinical activities and pipeline advancement. Peter provides advisory support to multiple emerging biotechnology companies enhancing their product development initiatives. He holds a position on the Board of Directors at Jellatech, Inc.
   
  Peter is a Danish citizen and holds a PhD in developmental biology from Copenhagen University and maintains an adjunct professor appointment at the Johns Hopkins School of Medicine. He has authored over 40 scientific papers and patents.

• 

  MSc

  Fabien Moncaubeig

  Chief Platform Officer

  Fabien Moncaubeig has been with TreeFrog Therapeutics since the outset and was appointed to his current position in September 2024.

  Fabien started with Treefrog Therapeutics as an advisor before the company was officially established. He served as a part-time interim Chief Operating Officer after its founding, then transitioned to a full-time role and was appointed Chief Development Officer in 2020.
  
  Fabien Moncaubeig has over 15 years of expertise in the industrialization of cell and gene therapies. His first decade of experience, at PALL Lifesciences (now Cytiva), was dedicated to developing innovative cell culture technologies (adherent, suspension and fixed bed bioreactors) while optimizing, scaling up and industrializing cell and gene therapies ranging from preclinical to phase III. He was the lead of Process Development and Application Specialist teams located in EU, US and Asia. In 2017, he co-founded a CDMO specialized in Cell therapy (Cell-Easy) in which he built the R&D and Process Development team as Chief Technology Officer. Fabien is currently a Strategic Advisor for Biothrust, a company developing innovative bioreactors and has served as Strategic and Scientific Advisor at Goliver Therapeutics for 5 years.
  
  Fabien holds a Master’s degree in Biotechnology from ENSTBB, Bordeaux and contributed to numerous papers, articles, posters and patents.